These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 20195266)

  • 1. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.
    Adkins DE; Aberg K; McClay JL; Bukszár J; Zhao Z; Jia P; Stroup TS; Perkins D; McEvoy JP; Lieberman JA; Sullivan PF; van den Oord EJ
    Mol Psychiatry; 2011 Mar; 16(3):321-32. PubMed ID: 20195266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.
    Clark SL; Souza RP; Adkins DE; Aberg K; Bukszár J; McClay JL; Sullivan PF; van den Oord EJ
    Pharmacogenet Genomics; 2013 Feb; 23(2):69-77. PubMed ID: 23241943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.
    McClay JL; Adkins DE; Aberg K; Bukszár J; Khachane AN; Keefe RS; Perkins DO; McEvoy JP; Stroup TS; Vann RE; Beardsley PM; Lieberman JA; Sullivan PF; van den Oord EJ
    Neuropsychopharmacology; 2011 Feb; 36(3):616-26. PubMed ID: 21107309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.
    McClay JL; Adkins DE; Aberg K; Stroup S; Perkins DO; Vladimirov VI; Lieberman JA; Sullivan PF; van den Oord EJ
    Mol Psychiatry; 2011 Jan; 16(1):76-85. PubMed ID: 19721433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomewide association study of movement-related adverse antipsychotic effects.
    Aberg K; Adkins DE; Bukszár J; Webb BT; Caroff SN; Miller DD; Sebat J; Stroup S; Fanous AH; Vladimirov VI; McClay JL; Lieberman JA; Sullivan PF; van den Oord EJ
    Biol Psychiatry; 2010 Feb; 67(3):279-82. PubMed ID: 19875103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.
    Adkins DE; Clark SL; Åberg K; Hettema JM; Bukszár J; McClay JL; Souza RP; van den Oord EJ
    Transl Psychiatry; 2012 Jul; 2(7):e129. PubMed ID: 22760553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.
    Clark SL; Adkins DE; Aberg K; Hettema JM; McClay JL; Souza RP; van den Oord EJ
    Psychol Med; 2012 Jun; 42(6):1151-62. PubMed ID: 22041458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.
    Meyer JM; Davis VG; Goff DC; McEvoy JP; Nasrallah HA; Davis SM; Rosenheck RA; Daumit GL; Hsiao J; Swartz MS; Stroup TS; Lieberman JA
    Schizophr Res; 2008 Apr; 101(1-3):273-86. PubMed ID: 18258416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study.
    Yu H; Yan H; Wang L; Li J; Tan L; Deng W; Chen Q; Yang G; Zhang F; Lu T; Yang J; Li K; Lv L; Tan Q; Zhang H; Xiao X; Li M; Ma X; Yang F; Li L; Wang C; Li T; Zhang D; Yue W;
    Lancet Psychiatry; 2018 Apr; 5(4):327-338. PubMed ID: 29503163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing the role of genetic variation of the MC4R gene in Chinese population in antipsychotic-induced metabolic disturbance.
    Zhang Y; Ren H; Wang Q; Deng W; Yue W; Yan H; Tan L; Chen Q; Yang G; Lu T; Wang L; Zhang F; Yang J; Li K; Lv L; Tan Q; Zhang H; Ma X; Yang F; Li L; Wang C; Zhang D; Zhao L; Wang H; Li X; Guo W; Hu X; Tian Y; Ma X; Li T;
    Sci China Life Sci; 2019 Apr; 62(4):535-543. PubMed ID: 30929193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-Wide Association Study Suggested the PTPRD Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications.
    Yu H; Wang L; Lv L; Ma C; Du B; Lu T; Jin C; Yan H; Yang Y; Li W; Ruan Y; Zhang H; Zhang H; Mi W; Mowry B; Ma W; Li K; Zhang D; Yue W
    Schizophr Bull; 2016 May; 42(3):814-23. PubMed ID: 26656879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches.
    Ikeda M; Tomita Y; Mouri A; Koga M; Okochi T; Yoshimura R; Yamanouchi Y; Kinoshita Y; Hashimoto R; Williams HJ; Takeda M; Nakamura J; Nabeshima T; Owen MJ; O'Donovan MC; Honda H; Arinami T; Ozaki N; Iwata N
    Biol Psychiatry; 2010 Feb; 67(3):263-9. PubMed ID: 19850283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.
    Malhotra AK; Correll CU; Chowdhury NI; Müller DJ; Gregersen PK; Lee AT; Tiwari AK; Kane JM; Fleischhacker WW; Kahn RS; Ophoff RA; Meltzer HY; Lencz T; Kennedy JL
    Arch Gen Psychiatry; 2012 Sep; 69(9):904-12. PubMed ID: 22566560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin.
    Fernández E; Carrizo E; Fernández V; Connell L; Sandia I; Prieto D; Mogollón J; Valbuena D; Fernández I; de Baptista EA; Baptista T
    Schizophr Res; 2010 Aug; 121(1-3):213-7. PubMed ID: 20591628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between SREBF2 gene polymorphisms and metabolic syndrome in clozapine-treated patients with schizophrenia.
    Yang L; Chen J; Liu D; Yu S; Cong E; Li Y; Wu H; Yue Y; Zuo S; Wang Y; Liang S; Shi Y; Shi S; Xu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():136-41. PubMed ID: 25201120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.
    Sacchetti E; Magri C; Minelli A; Valsecchi P; Traversa M; Calza S; Vita A; Gennarelli M
    Pharmacogenomics J; 2017 Mar; 17(2):146-154. PubMed ID: 26856250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of genome-wide association studies of antipsychotic response.
    Allen JD; Bishop JR
    Pharmacogenomics; 2019 Mar; 20(4):291-306. PubMed ID: 30883267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes.
    Stevenson JM; Reilly JL; Harris MS; Patel SR; Weiden PJ; Prasad KM; Badner JA; Nimgaonkar VL; Keshavan MS; Sweeney JA; Bishop JR
    Transl Psychiatry; 2016 Feb; 6(2):e739. PubMed ID: 26905411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
    Houston JP; Kohler J; Bishop JR; Ellingrod VL; Ostbye KM; Zhao F; Conley RR; Poole Hoffmann V; Fijal BA
    J Clin Psychiatry; 2012 Aug; 73(8):1077-86. PubMed ID: 22967772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.